Introduction
Intracranial gliomas are intrinsic brain tumours that are classified according to their histological features by the WHO grading system. WHO grade IV gliomas (glioblastoma multiforme, GBM) carry the worst prognosis with an overall survival of often less than 12 months [1] . WHO grade II gliomas feature a better prognosis with a median survival of 8-10 years. WHO grade III gliomas (anaplastic gliomas) exhibit a prognosis closer to GBM than to the grade II gliomas; grade I gliomas are regarded as potentially curable.
The resection of GBM, followed by combined radiochemotherapy, is accepted as the current therapeutic standard [2] . A high extent of resection was found to be positively correlated with prolonged time to tumour recurrence [1, 3, 4] . Different technical developments such as 5-aminolevulinic acid for intraoperative tumour visualization [5] , navigational systems or intraoperative MRI [6, 7] allow a high extent of resection to be achieved. However, if the tumour is critically located in brain areas that are responsible for functions such as speech or motor function, this aggressive therapeutic approach often cannot be efficiently applied. Preservation of functions is a major goal, and so the extent of resection needs to be limited. This results in higher residual tumour volumes, which represent suboptimal prerequisites for adjuvant radiochemotherapy. In the less aggressive low-grade gliomas (WHO grade II), the situation is more complex: therapeutic recommendations range from the "wait and see" strategy over radiotherapy and/or chemotherapy to an initial radical resection [8] [9] [10] [11] [12] . If low-grade gliomas are functionally critically located and affect important neurological functions of the patient, there is even more therapeutic insecurity whether taking a higher risk for functional deterioration improves the patient's overall outcome.
Besides treatment of the main tumour mass, therapy of the infiltration zone needs to be addressed as a major goal, because 95% of gliomas exhibit local recurrence [13] .
WHO grades II-IV gliomas have been shown to consistently overexpress the transmembraneous neurokinin type-1 receptor (NK-1). NK-1 receptors have also been detected on tumour cells infiltrating the intra-and peritumoural vasculature [14] . The physiological ligand of NK-1 receptors is substance P. The local intratumoural injection of radiolabelled substance P exploits this overexpression of the NK-1 receptor. Substance P can be radiolabelled with various radionuclides for diagnostic or therapeutic applications using the chelators DOTAGA (1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid) or DOTA (1,4,7,10-tetraazacy clododecane-1,4,7,10-triacetic acid). Radiolabelled DOTAGA-/DOTA-substance P exhibits a preserved affinity to the NK-1 receptor in the low nanomolar range; the in vivo stability has been confirmed [15] . Its molecular weight of only 1.8 kDa facilitates sufficient and rapid intratumoural distribution after local application. Treatment with 90 Y-labelled substance P led to good functional outcome and a trend toward improved survival when evaluated as a second-line treatment for recurrent gliomas [15] . Tumour resection following this treatment was significantly facilitated by radiation necrosis and pseudoencapsulation of the tumour. We conducted another study to evaluate this treatment as a neoadjuvant modality:
90 Y-labelled substance P was locally injected after biopsy confirmation of GBM, followed by resection of the pretreated glioma. This concept was feasible without signs of decompensating intracranial pressure and relevant toxicity. Of 16 patients, 14 stabilized or improved their neurological function; the pseudocapsule-like tumour demarcation allowed a high extent of resection to be achieved in subsequent surgery (submitted). The radionuclide used in these studies, 90 Y, has several advantageous characteristics: β-particle emitter with a mean energy of 2.1 MeV, mean tissue range of 5 mm, commercially available and standardized handling. However, in functionally critical areas of the brain, the tissue range of 90 Y with the resulting "cross-fire effect" [16] potentially damages adjacent brain areas. Alternatively, α-particleemitting radionuclides may be powerful candidates:
213 Bi as an example has a mean tissue range of only 81 µm with a high mean energy of 5.8 MeV, allowing a highly cytotoxic radiation dose to be delivered to targeted cells while sparing adjacent healthy tissue.
Targeted alpha therapy using 213 Bi has been shown to exhibit a favourable toxicity profile and therapeutic potential in phase 1 trials in leukemia, non-Hodgkin's lymphoma and melanoma [17] [18] [19] . The short-lived alpha emitter 213 Bi (T 1/2 =46 min) is available from a radionuclide generator loaded with its longer-lived mother nuclide 225 Ac (T 1/2 =10 days), which can be produced via radiochemical extraction from 229 Th [20] or cyclotron-driven methods [21] . In this pilot study, we present the results of five patients with WHO grades II-IV gliomas who have been treated with locally injected 213 Bi-DOTA-substance P as the primary therapeutic modality. Besides feasibility and toxicity as primary end-points, the functional outcome was examined as a secondary end-point.
Materials and methods

Patients
Study patient data are summarized in Table 1 . The study protocol had been approved by the Ethics Committee of the University Hospitals of Basel, Switzerland. Patients meeting the inclusion criteria were informed about current therapy options. The rationale for inclusion of patients with WHO grade II tumours is, despite the better prognosis than the high-grade gliomas, the still life-limiting character of the disease. Informed consent was obtained before inclusion. The functional status was assessed using the Barthel Index, which evaluates neurological function by evaluating the impairment in activities of daily living [22] . Tumour volumetry was performed using the software IPlan2.6 (BrainLAB, Feldkirchen, Germany).
Inclusion criteria
The criteria for inclusion were: newly diagnosed and histopathologically confirmed unifocal glioma (WHO grades II-IV); tumour diameter max. 5 cm; no evidence for obstruction of CSF circulation or decompensating intracranial pressure; Karnofsky performance score ≥70; age 18-75 years; absence of psychological, familial, sociological or geographical conditions potentially hampering compliance with the study protocol.
Study protocol
Week 1: stereotactic biopsy, intratumoural implantation of catheter systems (Fig. 1) . In tumours ≤3 cm in diameter one catheter was implanted and in larger tumours or those with complex configuration two or three catheters. Week 2: local test injection with 111 In-DOTA-substance P for confirmation of positive NK-1 receptor expression and orthotopic dose distribution. Week 3: intratumoural injection of 213 Bi-DOTA-substance P. Depending on clinical and radiographic findings: repetition of intratumoural injection, otherwise post-therapeutic evaluation as depicted below. Tumour resection after radiopeptide treatment was offered if the operation was feasible and of probable benefit. In cases of tumour progression/recurrence: histology by biopsy or, if feasible, by tumour resection; combined with chemotherapy and/or external beam radiotherapy.
11 ]-substance P was synthesized as described for the corresponding DOTAGA derivative [15] .
Production of 225
Ac/ 213 Bi, radiolabelling and stability testing 225 Ac/ 213 Bi was produced at the Institute of Transuranium Elements (Karlsruhe, Germany) by radiochemical extraction from a 229 Th source [20, 23] . 213 Bi was eluted from a 225 Ac/ 213 Bi-generator using 600 µl 0.1 M NaI/HCl (Merck, Darmstadt, Germany, suprapure grade) solution. Addition of 50 µl of 20% ascorbic acid (Prolabo, VWR International, Fontenay sous Bois, France, normapure grade) as radioprotectant, pH adjustment to 8.5-8.7 with 70 µl of 2 M Na 2 CO 3 (Merck, Darmstadt, Germany, suprapure grade). Incubation of buffered 213 Bi eluate (270-1174 MBq) with 10 µg (n=5, patient 1) or 30 µg (n= 22, patients 2-5) DOTA-substance P for 5 min at 95°C in a microwave oven (Biotage Initiator, Uppsala, Sweden) and addition of 30 µl 1 mM Ca-DTPA to complex-free 213 Bi [24] . Quality control by standard gradient radio-HPLC using a Chromolith Speed ROD RP-18 endcapped 50-4.6 mm column (Merck, Darmstadt, Germany) with acetonitrile-water gradient and ion thin-layer chromatography (ITLC-SG, Pall Inc., New York, NY, USA) using 0.05 M sodium citrate solution (pH 5.5) as mobile phase, followed by sterile filtration. Synthesis, quality control and sterile filtration of 213 Bi- 11 ]-substance P in the presence of a 250-fold excess of DTPA as competing ligand using radio-HPLC. In this study, a very slow release of 213 Bi with a half-life of 185 h was found.
Injection of the radiopharmaceutical
Intratumoural injection of the radiopharmaceutical is performed via one to three implanted catheters [25] [26] [27] . The catheter is connected to a subcutaneous port, which is punctured for injection (Fig. 1) . Application of 12 mg dexamethasone and, immediately before injection, 60 g mannitol transiently reduces intratumoural pressure. Before injection, the system is flushed with 1.5 ml human albumin 5% to coat the plastic surface. The active drug is injected in a volume of 1 ml. Finally, the system is flushed again with 1.5 ml human albumin. For each therapeutic cycle, three to five injections were performed over 2 days.
Evaluation of receptor expression and dose distribution
Each patient was injected with 1 MBq of 111 In-DOTA-[Thi 8 ,Met(O 2 ) 11 ]-substance P per catheter as test injection before therapy. Images were acquired immediately after injection and 4 and 24 h after injection to confirm stable and orthotopic dose distribution. The images were acquired as 3-D data set (SPECT and low-dose CT) using an integrated dual-head SPECT/CT camera (SYMBIA T 2 , Siemens, Malvern, PA, USA) and automatic fusion. 111 In SPECT images were acquired in continuous scan mode (25 min/rotation). The windows were centred over both 111 In photon peaks (245 and 172 keV, width ±20%). Therapeutic activities were administered only if the activity was found stable within the tumour, i.e. no dose deposition outside the tumour margins on SPECT/CT over 24 h which was interpreted as specific binding.
After every application of 213 Bi-DOTA-[Thi 8 ,Met (O 2 ) 11 ]-substance P, SPECT/CT was acquired to confirm orthotopic dose deposition. For SPECT, the window was centred at 440 keV (width ±20%). SPECT was acquired with 128 views; acquisition time was 10 s/view.
Blood sampling was performed until 4 h after injection. Aliquots of 3 ml were analysed for 213 Bi activity using a NaI(Tl) bore well counter (COBRA II, D 5003 γ-system, Canberra Packard, Melbourne, Australia). The percentage of injected 213 Bi in the blood pool was determined based on calculated total blood volumes.
Post-therapeutic evaluation
Patients were clinically evaluated weekly within the first 8 weeks after radiopeptide application, afterwards monthly for the grade III and IV tumours and in 3-month intervals for the grade II tumours. MR imaging was performed monthly after injection of the radiopharmaceutical for the first 3 months, thereafter in 3-month intervals for the grade III and IV tumours and in 6-month intervals for the grade II tumours.
Results
Patient characteristics and functional status
Two patients with low-grade astrocytomas (WHO grade II), one patient with anaplastic glioma (WHO grade III) and two patients with GBM (WHO grade IV) in functionally critical locations were treated with intratumourally injected 213 Bi-DOTA-substance P as the primary therapeutic modality ( Table 1 ). The preliminary diagnosis from the freshfrozen sections was confirmed by definite histology in all cases. Four patients received 1.07-2.00 GBq 213 Bi-DOTAsubstance P within one therapeutic cycle, and one patient received four therapeutic cycles with a total activity of 7.36 GBq. The pre-therapeutic functional score, evaluated by the Barthel Index [22] , was 100 out of 100 in the patients with the WHO grade II and III tumours (patients 3, 4 and 5). In these patients, this unimpaired functional status did not change during or after treatment. The two GBM patients displayed pre-therapeutic Barthel scores of 75 (patient 1) and 80 (patient 2), which means moderate restrictions in activities of daily living. Both GBM patients improved to a score of 90 after treatment, being consistent with minor impairment in daily living (Table 1) .
Biodistribution and pharmacokinetics Positive NK-1 receptor expression was demonstrated by test injection of 111
In-DOTA-substance P in all patients. The dose distribution of the test injection was congruent with tumour morphology in all cases. The sufficient dose distribution expected from pre-therapeutic test injections could be verified in all cases by post-therapeutic assessment by SPECT/CT imaging ( shown as examples in Figs. 4d-f and 6m-n). High retention of 213 Bi-DOTA-substance P at the target site was furthermore confirmed by low percentage values of the injected dose (%ID) in the blood pool. Maximum values of < 4%ID were found at 60-90 min after injection (Fig. 2a) . At these time points 50-75% of the injected activity of short-lived 213 Bi (T 1/2 = 46 min) have already decayed. Consequently, 213 Bi activities found in the 4 weeks after radiopeptide application and after partial resection of the tumour, d 6 weeks after radiopeptide application highly suspicious for tumour progression and e 8 weeks after radiopeptide application with evident tumour progression blood pool corresponded to less than 2% of the activities injected intratumourally (Fig. 2b) .
Patient characteristics and response
Patient 1 exhibited a bifrontal GBM; due to the limited prognosis she was initially not considered as an operative candidate. Local injection of 1.07 GBq 213 Bi-DOTAsubstance P resulted in intratumoural disseminated changes strongly suggestive for radionecrosis in MR imaging, but on the other hand, volumetric expansion of the tumour was noted. Subsequent partial resection confirmed the radiographic suspicion of radionecrosis and relieved the patients' mental status changes. MR imaging revealed tumour recurrence after only 1 month after the operation (i.e. 2 months after radiopeptide application), whereas the clinical improvement was stable for 10 months (Fig. 3) .
Because only about 50% of the tumour volume in patient 1 displayed radionecrotic changes in MR imaging and due to the absence of any signs of toxicity, the dose in patient 2 was increased to 1.92 GBq. Patient 2 initially presented with right-sided hemiparesis and motor dysphasia due to a left frontal GBM, affecting the precentral gyrus and the supplemental motor area (SMA). She clinically improved after radiopeptide treatment, becoming ambulatory again. Radiologically, the tumour demarcated with findings suspicious for radionecrosis (Fig. 4a-c) . According to the patient's wish, the pretreated tumour was resected. A "radical" resection was, due to the location of the tumour, not possible. First clinical and radiographic signs of tumour progression were observed 11 months later. The GBM patients (patients 1 and 2) were postoperatively treated with external beam radiotherapy and temozolomide chemotherapy according to the current therapeutic standard.
The anaplastic left fronto-opercular astrocytoma (WHO grade III) of patient 3 exhibited a diameter of 5 cm, causing dysphasia. Radiographic changes after injection of 213 Bi-DOTA-substance P, suggestive for radionecrosis, were observed mainly in proximity to the catheters in cortical and apical parts of the tumour, only to a much lesser extent in deep and basal parts (Fig. 5) . The catheters were repositioned and patient 3 received further therapeutic cycles. The distribution of radiological signs of radionecrosis did not significantly change in the further course, but interest- Patient 4 initially complained about fatigue, accompanied by left-sided partial brachiofacial seizure equivalents and facial paresis. MR imaging displayed a right-sided and non-contrast enhancing mass of the SMA extending to the precentral gyrus (Fig. 6a, b) ; biopsy revealed a WHO grade II astrocytoma. Injection of 1.96 GBq 213 Bi-DOTA-substance P resulted in extensive demarcation of the tumour (Fig. 6c-f) . According to the patient's wish, the tumour was subsequently resected. Intraoperatively, the lesion appeared as a necrotic and well-defined encapsulated mass, enabling macroscopic complete tumour removal. Follow-up imaging is so far without evidence for recurrent tumour (Fig. 6g-l) . The patient's fatigue improved and the facial paresis has resolved; anticonvulsive prophylaxis was continued because of electroencephalographic findings of focal epilepsyspecific potentials.
Patient 5 presented with fatigue and headache, which led to the diagnosis of an occipital astrocytoma (WHO grade II). After local injection of 2.00 GBq 213 Bi-DOTAsubstance P there is evidence for extensive radionecrotic demarcation of the tumour in repetitive MR imaging in the post-therapeutic follow-up (Fig. 7) . The clinical condition of this patient did not change in the course of treatment.
Side effects and toxicity
Intratumourally injected 213 Bi-DOTA-substance P was tolerated well by all patients; no relevant acute local or systemic toxicity could be found according to the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) scale (version 2.0). In the long-term follow-up, no further substantial local or systemic toxicity was found. Corticosteroid therapy generally was tapered 2 weeks after radiopeptide application. Bi-DOTA-substance P injection. e, f Status 7 months after radiopeptide injection; note that the lesion appears slightly more compact. g, h Imaging 19 months after radiopeptide treatment, most probably consistent with local scar tissue formation
Discussion
Functionally critically located malignant gliomas still represent an immense therapeutic challenge, because often the therapeutic standards for an aggressive local therapy, i.e. surgery and radiotherapy, cannot be applied. There is no doubt about the importance of sufficient local control of high-and low-grade gliomas, since virtually all of them exhibit local recurrence. In critically located gliomas, the current technical developments for a higher extent of surgical resection [5, 7, 28] are only partially useful because in this entity of tumours they carry a high risk of damaging neurological function. Awake surgery and/or intraoperative monitoring techniques represent valuable tools to avoid postoperative neurological deficits such as loss of motor function or speech, but remain without therapeutic effect on the prognostically pivotal infiltration zone. Consequently, patients with critically located gliomas are often not considered as candidates for an aggressive local therapy.
The fact that WHO grades II-IV gliomas do consistently overexpress NK-1 receptors led to the therapeutic local application of the radiolabelled NK-1 ligand DOTAGA-/ DOTA-substance P. The concept, besides treatment of the main mass, is a targeted approach to tumour cells in the surrounding infiltration zone. Previous studies have shown feasibility and low toxicity of this method as a second-line therapy [15] as well as in a neoadjuvant setting (submitted). However, the radionuclide 90 Y, which was used in these previous studies, may lead to unacceptable damage to adjacent brain areas because of its relatively high mean tissue range of 5 mm. The possibility of using 213 Bi instead of 90 Y may be a safer and even more efficacious alternative: The mean tissue range is only 81 µm with a high mean energy of 5.8 MeV ( 90 Y: 2.1 MeV), corresponding to a high linear energy transfer (LET) of 72 keV/µm. Consequently, the distance between ionizing events caused by alpha particle emission of 213 Bi is similar to the distance between DNA double strands, thus increasing the probability of inducing irreparable DNA double strand breaks. These prerequisites led to the design of the pilot study presented in this work: The histological diagnosis of a glioma in patients with eloquently located tumours was established by biopsy, followed by implantation of intratumoural catheters. Subsequently, 213 Bi-DOTAsubstance P was intratumourally injected as the primary therapeutic modality. SPECT/CT and blood sampling confirmed high retention of the radiopharmaceutical at the tumour site, in agreement with absence of toxicity to nontargeted, healthy brain tissue or other organs. MR imaging showed intratumoural changes highly suspicious for radionecrosis, which was confirmed by histopathological examination. Small tumours exhibited a complete radionecrotic appearance, whereas larger tumours seemed to be mainly necrotic in the proximity of the implanted catheters. This observation is probably due to the fact that the physical half-life of 213 Bi is only 46 min, so that a significant fraction of this radionuclide is possibly decayed before a sufficient intratumoural distribution is achieved. In large tumours, possibly different radionuclides such as 225 Ac with longer half-lives could be more efficacious. However, in one of two GBM patients and in the patient with the anaplastic glioma there is, despite incomplete radionecrotic demarcation of the tumours, a long time interval to further progression, so that possibly there is also a therapeutic effect in areas without radiographic evidence for radionecrosis. To the contrary, the first GBM patient, who received a relatively low dose, had only a short time interval to tumour progression. This observation may indicate a dose-effect relationship that needs to be confirmed in a larger number of patients.
The most benefit from the application of 213 Bi-labelled substance P is probably seen in the patients with relatively small tumours (12.0 and 17.1 cm 3 ), where sufficient intratumoural distribution could be achieved. Radiographically these tumours are completely necrotic demarcated; in the one patient operated on after radiopeptide therapy there was no evidence for viable tumour cells in the surrounding area. It is remarkable that the demarcated area is much larger than the radiographically evident tumour area on initial MR imaging, being indicative for the real tumour dimensions and suggestive for a therapeutic effect in the infiltration zone. Consequently, patients with small, symptomatic gliomas may be ideal candidates for this therapeutic modality: there is no significant risk for decompensation of the intracranial pressure and the intratumoural distribution of the radiopharmaceutical is sufficient to target the entire mass as well as tumour cells in the infiltration zone. For these reasons, further evaluation of this concept in this subgroup of gliomas is planned.
Conclusion
Targeted therapy of critically located WHO grade II-IV gliomas with locally injected 213 Bi-DOTA-substance P is feasible and without relevant toxicity. Compared to therapeutic approaches using beta emitters, the treatment of gliomas using short-range alpha emitters may allow similar efficacy to be achieved with lower toxicity to healthy brain areas. Due to the relatively short half-life of 213 Bi, this innovative concept probably has most of its therapeutic potential in the treatment of small, critically located gliomas and is planned for further evaluation in this group of patients.
